INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Zogenix, Inc. Investors

Law Offices of Howard G. Smith announces an investigation on behalf of Zogenix, Inc. investors (Zogenix or the Company) (NASDAQ: ZGNX) concerning the Company and its officers possible violations of federal securities laws.

On April 8, 2019, Zogenix announced that it received a refusal to file letter from the U.S. Food and Drug Administration (FDA) regarding Zogenixs new drug application (NDA) for FINTEPLA, Zogenixs proposed treatment for seizures associated with Dravet syndrome. The FDA determined that the NDA was not sufficiently complete to permit a substantive review because certain non-clinical studies were not submitted to allow assessment of the chronic administration of fenfluramine, and the application contained an incorrect version of a clinical dataset. On this news, shares of Zogenix fell $11.89 or nearly 23% to close at $39.96 per share on April 9, 2019, thereby injuring investors.

If you purchased Zogenix securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
[email protected]